Skip to content
Buy

Science

Science It's real.

Peer-reviewed clinical research, independent trials, and regulatory recognition. Every claim about ProGo® is backed by evidence.

Invested in research
+$50M
Years of study
+10
Published studies
+8
FDA statements
13
Countries
+80
Bioavailability
98%

Peer-reviewed research

Clinical trials and published studies

Over $50 million invested and more than a decade of independent research. An index of studies supporting the bioactives in each stick.

  1. Clinical trial

    Iron-deficiency anemia: ferritin and hemoglobin levels after ProGo® supplementation versus whey protein

    Journal of Nutrition & Food Sciences · 2015

    n = 48 · placebo-controlled vs. whey isolate · 6 weeks · 16 g/day

    +140% ferritin (restored to normal levels); +14% hemoglobin versus +2% in the serum group (p<0.05). Based on 6 FDA statements and qualified Health Canada claims.

    View study
  2. Clinical trial

    Weight management and metabolic biomarkers: a randomized, placebo-controlled study on BMI in overweight adults

    Journal of Nutrition & Food Sciences

    Overweight adults · placebo-controlled vs. WPI · 42 days · 16 g/day

    -5.9% BMI (p<0.05); significant changes in 4 serum biomarkers of metabolism; consistent 3-6% reduction in fasting glucose.

    View study
  3. Clinical trial

    18-Week Efficacy of Salmon Protein Hydrolysate on Metabolic Inflammation, Well-being, and Cosmetic Outcomes

    Functional Foods in Health and Disease · 2024 · Vol. 14(11): 814–842

    n = 20 · open-label, single-arm · 128 days · 4 g/day · KGK Science Inc.

    +10.24% perceived energy (women +14.55%); -9% oxidative stress; HMOX1 ×4.09 and FTH1 ×3.77; skin, hair, and nails +24% (women +34.5%); reduced IL-5, IL-8, and CRP.

    View study
  4. Study published

    Randomized, double-blind, crossover study comparing the increase in blood leucine after ingesting hydrolyzed salmon protein and whey protein in healthy young men

    Nutrition & Food Technology Open Access · 2017

    n = 6 · double-blind crossover · 16 g dose · Norwegian School of Sport Sciences

    ProGo® achieved peak blood leucine 15 minutes sooner than WPC-80; rapid aminoacidemia; comparable insulin response.

    View study
  5. In vitro

    First exploration of in vitro activation of GLP-1 and GIP receptors and pancreatic islet cell protection by salmon bioactive peptides

    Marine Drugs (MDPI) · 2024 · 22(11): 490

    In vitro · Currie C. et al. · Hofseth BioCare

    The smallest peptide fraction of ProGo® activates GLP-1 and GIP receptors; protects pancreatic islet cells; inhibits DPP-IV; and improves glucose uptake in muscle.

    View study
  6. In vitro / Animal

    Soluble protein hydrolysate ameliorates inflammation and gastrointestinal damage in TNBS-induced colitis in mice

    Biomolecules · 2022 · 12(9): 1287

    Mouse Colitis Model · Wei J. et al. · Stanford University and Hofseth BioCare

    ProGo® significantly reduced colon tissue damage, inflammatory cell infiltration, and oxidative stress. Upregulation of HMOX1 confirmed. Study led by Dr. Karl Sylvester (Stanford).

    View study
  7. In vitro

    Glucoregulatory Bioactivity of ProGo® Peptides: DPP-IV Inhibition and Glucose Uptake in Muscle Cells

    Marine Drugs (MDPI) · 2024

    In vitro · Hofseth BioCare

    ProGo® peptides showed potent DPP-IV inhibition and improved glucose uptake in muscle: they increase insulin action, promote satiety, and reduce metabolic disease risk factors.

    View study
  8. In vitro

    Antioxidant Gene Expression: ProGo® upregulates 16 oxidative protective genes, including FTH1, HMOX1, and ALOX12

    Hofseth BioCare / Stanford University · Preclinical

    Human cell lines · HBC and Stanford University

    ProGo® upregulated 16 oxidative protection genes and downregulated 9 oxidative stress genes. FTH1, HMOX1, and ALOX12 showed notable changes supporting the observed clinical benefits.

    View study

Regulatory recognition

Approved Statements in North America

ProGo® has achieved the highest levels of regulatory recognition available in North America. These are not marketing claims: these are statements recognized by health authorities and legally defensible.

NDI · FDA ProGo® has received New Dietary Ingredient (NDI) status from the FDA (2022) — the highest safety rating available in the U.S. market.

13

FDA (U.S.) · Structure/function claims

  • Iron and blood

    «Promotes healthy ferritin and hemoglobin levels.»

  • Iron and blood

    «Helps maintain iron-rich blood.»

  • Energy

    «Promotes energy use.»

  • Cellular production

    «It promotes red blood cell production.»

  • Gastrointestinal and Immune Health

    «Promotes gastrointestinal and immune system health.»

  • Iron absorption

    «It helps absorb iron from the daily diet.»

  • Skin

    «Help with dry skin.»

  • Skin

    «Reduces wrinkles and promotes skin smoothness.»

  • Skin barrier

    «Prevents increased transepidermal water loss.»

  • Skin

    «Promotes skin health and appearance.»

  • Fatigue

    «Reduces occasional fatigue and the overall feeling of occasional tiredness.»

  • Antioxidant

    «Reduces oxidative stress caused by free radicals.»

  • Antioxidant

    «It acts as an antioxidant.»

4

Health Canada · Qualified claims

  • Iron and blood

    «Helps maintain healthy ferritin and hemoglobin levels.»

  • Oxygen transport

    «Helps maintain healthy levels of blood components necessary for oxygen transport.»

  • Antioxidant

    «Provides antioxidants for the maintenance of good health.»

  • Skin

    «Helps promote healthy skin.»

ProGo® is Canada’s first and only iron-free product with regulatory approval for iron health claims.

These statements apply specifically to ProGo® bioactive peptides manufactured and supplied by Hofseth BioCare ASA. Structure/function claims are compliant with 21 CFR 101.93 (U.S.); Health Canada qualified claims are governed by the Natural Health Products Regulations. This product is not intended to diagnose, treat, cure, or prevent any disease.

Independent research

With the best institutions

The science behind ProGo® is not homegrown: it is endorsed by independent research institutions and organizations.

Hofseth BioCare ASA

Ålesund · Norway

Origin and manufacturer of ProGo®: a patented and clinically validated bioactive peptide, derived from sustainable Norwegian Atlantic salmon trimmings. Listed on the Oslo Stock Exchange (HBC).

See your research

Stanford University

Palo Alto · California

Dr. Karl Sylvester led the benchmark study on gut health and colitis (Biomolecules, 2022), which confirmed the immunomodulatory action of ProGo® and the upregulation of HMOX1.

KGK Science Inc.

London, Ontario · Canada

Independent clinical research organization that conducted the 128-day trial on vitality, inflammation, and cosmetic outcomes (2024). One of North America’s leading CROs for nutraceutical trials.

In press

Norwegian mountain range above the fjord, the origin of ProGo® bioactives

Born in the fjords. Tested in the lab.

From Norwegian Atlantic salmon to a four-gram stick: a decade of research, measured with instrument precision.

Discover the ritual